



## PARADIGM SHIFT IN SCREENING TECHNIQUES FOR EARLY DIAGNOSIS OF PRE-RETINOPATHY CHANGES IN DIABETIC POPULATION

|                        |  |
|------------------------|--|
| <b>Purva S. Date</b>   | DNB, FVRS Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India.                       |
| <b>Neha H. Shah*</b>   | DOMS, DNB Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India. *Corresponding Author |
| <b>Swati Hire</b>      | DOMS, DNB Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India.                       |
| <b>Sanchit Bhalgat</b> | DOMS, DNB Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India.                       |
| <b>Avinash Ingole</b>  | MS Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India.                              |
| <b>Anamika Agarwal</b> | MS Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India.                              |
| <b>Saroj Sahdev</b>    | MS, FRF Department of Ophthalmology, T.N.M.C. BYL Nair Ch. Hospital, Mumbai Central. Mumbai, Maharashtra, India.                         |

### ABSTRACT

**Aims and Objective:** To evaluate role of OCT based Retinal nerve fibre layer (RNFL) thickness and GCC (Ganglion cell complex) thickness measurement for detection of pre retinopathy changes in diabetic patients. **Methods :** This a comparative cross-sectional study of two groups of 110 eyes were examined by SD-OCT with peripapillary RNFL, and macular GCC assessment. The study group includes 55 eyes of diabetic patients with no diabetic retinopathy changes with their age matched controls (55 eyes). Their RNFL thickness in superior, temporal, inferior and nasal quadrants and GCC thickness in supero-nasal, superior, supero-temporal, infero-temporal, inferior and infero-nasal were compared in both groups. **Results:** The two groups were matched concerning the age, gender and the intra-ocular pressure (IOP) level. A significant difference between the two groups was found for the average, as well as the 4 sectors thickness ( $p < 0.001$ ). The GCC thickness, was significantly less in the diabetic eyes in all 6 sectors and average ( $p < 0.001$ ). **Conclusion:** RNFL and GCC loss seems to be the earliest retinal changes in diabetic patients. These results can explain the neurodegeneration theory for diabetic retinopathy. OCT based screening of RNFL and GCC thickness can serve as an early biomarker of diabetic retinopathy.

**KEYWORDS :** Diabetic retinopathy, GCC RNFL thickness, ganglion cell, SD-OCT

### INTRODUCTION:

Diabetes retinopathy (DR) is a microangiopathy commonly seen in cases of diabetes mellitus (DM) patients. It is estimated that approximately 191 million people may be suffering from diabetes by year 2030<sup>1</sup>. DR is one of the leading causes of blindness in developed countries. Several studies have shown neural apoptosis, loss of ganglion cell bodies in the earlier stages of DR<sup>2</sup>

Retinal Nerve Fibre Layer (RNFL) and ganglion cell complex (GCC) are affected in several diseases like glaucoma, optic neuritis. In our study, GCC and RNFL thickness of diabetic patients with no clinical DR was compared with non-diabetic group. We wanted to evaluate the role of OCT as a diagnostic test which can serve as a biomarker to identify patients at risk of developing DR.

### MATERIALS AND METHODS

A comparative, cross sectional, observational study was conducted at a major tertiary care hospital in the department of Ophthalmology from July 2021 to January 2022. Patients were recruited as per the inclusion and exclusion criteria. Peripapillary RNFL and macular cube thickness was measured with Zeiss Cirrus HD 500 OCT model with software version 10.0.0.14618 of both eyes of patients of two groups that is diabetic patients without DR changes and their age matched normal patients. The GCC thickness and RNFL thickness was compared between the two groups. The study was compliant with the declaration of Helsinki statement and informed written consent was obtained from all patients to

participate in the study. Patients with moderate and severe NPDR, other macular pathology, other causes of retinopathy, high myopia, and those with suspected glaucoma were excluded from the study.

After detailed systemic and ocular history detailed ophthalmic evaluation including best corrected visual acuity (BCVA), Intra ocular pressure (IOP), slit lamp examination, dilated fundus evaluation and OCT was done. RNFL is measured in four quadrants and GCC is measured in 6 sectors. All automated readings were also checked by manual segmentation of RNFL & GCC and corrections applied.

### Statistical Analysis:

All data were analysed using the IBM SPSS Statistical program version 20, taking into consideration mean, median, standard deviation, range, coefficient of variation, independent t-test, bivariate analysis, and multivariate analysis. "P" values  $< .05$  were accepted as statistically significant, and all data is expressed as "mean  $\pm$  standard deviation". An independent samples t test was used to compare the studied ocular measurements between the study and control groups. When the Levene test P values were  $> .05$  for the studied variables, the independent samples t test was used. In cases in which assumptions for parametric t tests were violated, Mann-Whitney U test was used instead.

### RESULTS:

RNFL thickness in superior, temporal, inferior and nasal quadrants as shown in figure 1 and GCC thickness in supero-

nasal, superior, supero-temporal, infero-temporal, inferior and infero-nasal as shown in figure 2 were measured.

The table 1 shows that our two groups were well age and gender matched population. They were divided into two groups based on their 2 hour post prandial blood sugar. The parapapillary RNFL and macular GCC was significantly reduced in diabetic patients when compared to non-diabetic population also the independent t test among two group showed a p value of <0.001 as shown in table 2.

**Table 1:** Mean and standard deviation with p value by independent t test analysis matching the biological parameters of diabetic patients and the control group.

| Parameter | Group         | Mean +/- Std. Deviation  |
|-----------|---------------|--------------------------|
| Age       | Diabetics     | 51.92 +/- 11.712 µm      |
|           | Non-Diabetics | 54.27 +/- 9.405 µm       |
| Gender    | Diabetics     | 1.47 +/- 0.502 µm        |
|           | Non-Diabetics | 1.53 +/- 0.502 µm        |
| PPBS      | Diabetics     | 214.2364 +/- 91.39881 µm |
|           | Non-Diabetics | 111.9153 +/- 23.98502 µm |

**Table 2:** Mean and standard deviation with p value by independent t test analysis matching the OCT parameters of diabetic patients and the control group.

| Parameter          | Group         | Mean +/- Std. Deviation  | p-value |
|--------------------|---------------|--------------------------|---------|
| RNFL Temporal      | Diabetics     | 55.9273 +/- 11.59382 µm  | <0.001  |
|                    | Non-Diabetics | 66.2727 +/- 12.32876 µm  |         |
| RNFL Superior      | Diabetics     | 104.8818 +/- 24.87058 µm | <0.001  |
|                    | Non-Diabetics | 123.1727 +/- 16.64476 µm |         |
| RNFL Nasal         | Diabetics     | 63.7364 +/- 13.46124 µm  | <0.001  |
|                    | Non-Diabetics | 77.4727 +/- 12.75004 µm  |         |
| RNFL Inferior      | Diabetics     | 107.8636 +/- 26.87295 µm | <0.001  |
|                    | Non-Diabetics | 131.9273 +/- 18.47697 µm |         |
| Average RNFL       | Diabetics     | 83.1023 +/- 14.38607 µm  | <0.001  |
|                    | Non-Diabetics | 99.7114 +/- 11.53427 µm  |         |
| GCC Superotemporal | Diabetics     | 72.68 +/- 14.18 µm       | <0.001  |
|                    | Non-Diabetics | 83.27 +/- 9.061 µm       |         |
| GCC Superior       | Diabetics     | 72.11 +/- 17.661 µm      | <0.001  |
|                    | Non-Diabetics | 87.26 +/- 9.462 µm       |         |
| GCC Superonasal    | Diabetics     | 74.93 +/- 17.198 µm      | <0.001  |
|                    | Non-Diabetics | 87.45 +/- 9.377 µm       |         |
| GCC Inferonasal    | Diabetics     | 73.13 +/- 17.12 µm       | <0.001  |
|                    | Non-Diabetics | 87.45 +/- 9.377 µm       |         |
| GCC inferior       | Diabetics     | 69.58 +/- 17.665 µm      | <0.001  |
|                    | Non-Diabetics | 87.03 +/- 10.08 µm       |         |
| GCC Inferotemporal | Diabetics     | 72.85 +/- 16.24 µm       | <0.001  |
|                    | Non-Diabetics | 83.27 +/- 9.061 µm       |         |
| Average GCC        | Diabetics     | 72.61 +/- 15.484 µm      | <0.001  |
|                    | Non-Diabetics | 85.96 +/- 8.508 µm       |         |

Mean Average GCC in diabetic patient was 72.61 +/- 15.48 µm, whereas it was 85.96 +/- 8.50 µm in non-diabetic population. This difference was statistically significant (independent t test p value of <0.001) as shown in figure 3. Average RNFL thickness among the 2 groups. Mean Average RNFL thickness was 83.10 +/- 14.38 µm and 99.74 +/- 11.53 µm in diabetic patients and control group respectively as shown in figure 4.

**DISCUSSION:**

The exact cause of RNFL and GCC thinning is still unknown. It may be attributed to sub optimal perfusion of the inner retinal layers. Another possible mechanism is the decreased insulin level which leads to hyper-glycemia and accumulation of advanced glycation end products<sup>3</sup>. These in turn, may accelerate the apoptosis of neuroglial cells in the inner retinal layers.

In our study, the difference in RNFL and GCC in all sectors in age and gender matched diabetics and non-diabetics was statistically significant. Rodrigues EB et al and van Dijk HW showed comparable results<sup>4,2</sup>. Afef M. et al in their study concluded that the average, superior and inferior RNFL thickness was significantly reduced in diabetics<sup>5</sup>. Pekel E. et al found significant difference between the RNFL between diabetics and non-diabetics, only in the supero nasal quadrant<sup>6</sup>. Table 3 compares the RNFL thickness in diabetics and non-diabetics of their study with ours.

**Table 3:** Comparison of RNFL thickness data of various studies<sup>5,6</sup> with our study

| Study               | Afef M. et al study |               | Pekel E et al study |               | Our study      |                |
|---------------------|---------------------|---------------|---------------------|---------------|----------------|----------------|
|                     | Diabetics           | Non-diabetics | Diabetics           | Non-diabetics | Diabetics      | Non-diabetics  |
| Average RNFL in µm  | 89.7 ± 10.5         | 99.7 ± 20.6   | 95.1 ± 8.0          | 96.5 ± 6.6    | 83.10 ± 14.38  | 99.71 ± 11.53  |
| Temporal RNFL in µm | 64.5 ± 10.3         | 64.8 ± 11.8   | 66.1 ± 8.9          | 64.4 ± 9.3    | 55.92 ± 11.59  | 66.27 ± 12.32  |
| Superior RNFL in µm | 112.3 ± 11.3        | 115.6 ± 11.7  | 115.8 ± 13.5        | 119.7 ± 14.7  | 104.88 ± 24.87 | 123.17 ± 16.64 |
| Nasal RNFL in µm    | 72.6 ± 10.1         | 72.9 ± 13.1   | 73.0 ± 10.1         | 73.5 ± 9.1    | 63.73 ± 13.46  | 77.47 ± 12.75  |
| Inferior RNFL in µm | 114.2 ± 10.7        | 119.2 ± 12.3  | 125.6 ± 15.4        | 127.8 ± 11.5  | 107.86 ± 26.87 | 131.92 ± 18.47 |

We conclude that the GCC thickness in diabetics is significantly thinner than in age & gender matched controls. As per Afef M. et al, the sector wise as well as average GCC thickness was significantly reduced in diabetic patients<sup>5</sup>. As per Pekel E. et al the sectoral thickness values of GCC in the diabetic eyes were thinner than that of the controls, but this difference was statistically significant only in the superior-nasal area<sup>6</sup>. Table 4 compares GCC data of above studies with our study. In contrast to our findings, Pollreis A et al. [using PlexElite system (Carl Zeiss Meditec, Jena, Germany)] showed no significant difference between the ganglion cell layer complex between diabetics and non-diabetic population<sup>7</sup>. This may be attributed to combined measurement of RNFL, GCL and IPL taken by them.

**Table 4:** Comparison of GCC thickness data of various studies<sup>5,6</sup> with our study

| Study                     | Afef M. et al study     |                         | Pekel E et al study |               | Our study     |               |
|---------------------------|-------------------------|-------------------------|---------------------|---------------|---------------|---------------|
|                           | Diabetics               | Non-diabetics           | Diabetics           | Non-diabetics | Diabetics     | Non-diabetics |
| Average GCC in µm         | 80.6 ± 10.2             | 86.2 ± 8.5              | 82.2 ± 6.1          | 83.9 ± 4.7    | 72.61 ± 15.48 | 85.96 ± 8.50  |
| Superior GCC in µm        | 79.5 ± 7.4              | 85.6 ± 8.6              | 82.8 ± 6.8          | 84.8 ± 5.2    | 72.11 ± 17.66 | 87.26 ± 9.46  |
| Supero Temporal GCC in µm | Superior GCC 79.5 ± 7.4 | Superior GCC 85.6 ± 8.6 | 81.0 ± 6.3          | 81.7 ± 4.9    | 72.68 ± 14.18 | 83.27 ± 9.06  |
| Supero Nasal GCC in µm    | 79.5 ± 7.4              | 85.6 ± 8.6              | 82.7 ± 7.4          | 85.3 ± 5.7    | 74.93 ± 17.19 | 87.45 ± 9.37  |
| Inferior GCC in µm        | 73.8 ± 9.6              | 81.4 ± 7.8              | 81.4 ± 6.6          | 83.0 ± 4.8    | 69.58 ± 17.66 | 87.03 ± 10.08 |

|                                      |                |                |                |                |                   |                  |
|--------------------------------------|----------------|----------------|----------------|----------------|-------------------|------------------|
| Infero Nasal GCC in $\mu\text{m}$    | Inferior GCC   | Inferior GCC   | 82.3 $\pm$ 7.0 | 84.3 $\pm$ 6.0 | 73.13 $\pm$ 17.12 | 87.45 $\pm$ 9.37 |
| Infero Temporal GCC in $\mu\text{m}$ | 73.8 $\pm$ 9.6 | 81.4 $\pm$ 7.8 | 82.9 $\pm$ 6.4 | 84.1 $\pm$ 4.6 | 72.85 $\pm$ 16.24 | 83.27 $\pm$ 9.06 |

Pre retinopathy may also be evaluated by assessment of retinal function tests. Reis A, et al used psychophysical tests of ganglion cell and electro-physiological recordings (mfERG) for same. They noted reduced retinal neuronal function in type 1 diabetic patients with no clinically diagnosed DR<sup>8</sup>.

The limitation of our observational study could be the sample size. A prospective randomized control trial with larger sample size is required to establish the role of OCT based screening of RNFL and GCC thickness as an early risk factor for development diabetic retinopathy.

Gold standard methods for diagnosis and screening of DR have been clinical slit lamp biomicroscopy and fundus photography. However, there have been significant technological advances which can aid in diagnosis of pre-retinopathy, even before setting in of clinically apparent diabetic retinopathy. Fundus photography with incorporated Artificial Intelligence<sup>9</sup>, OCT Angiography (OCTA)<sup>10</sup> and GCC and RNFL thickness analysis are capable of this and should be incorporated in DR screening protocols.

#### CONCLUSION:

OCT of peripapillary RNFL and macular cube for GCC thickness are quite reliable for diagnosis of pre-retinopathy in diabetic individuals. It can serve as a biomarker to identify patients at risk of developing diabetic retinopathy. However larger sample size may throw further light of above. A follow up scan of these patients after 2 years and 5 years. Is to be planned for further analysis of how these patients develop diabetic retinopathy and its effect on the GCC and RNFL needs to be done.

**Conflicts of Interest & Financial disclosure:** None of the authors have any financial/ conflicting interests to disclose.

**Funding-**None

**Data Availability:** On request, data can be made available. Corresponding author has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Acknowledgment section:** None

**Key Messages:** Screening for diabetic retinopathy can be further enhanced by OCT analysis for RNFL and Ganglion cell layer thickness. As it seems to be the early diagnostic factor for developing diabetic retinopathy.

#### REFERENCES:

- Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. 2012;4.
- van Dijk HW, Verbraak FD, Kok PHB, Garvin MK, Sonka M, Lee K, et al. Decreased Retinal Ganglion Cell Layer Thickness in Patients with Type 1 Diabetes. *Investig Ophthalmology Vis Sci*. 2010 Jul 1;51(7):3660.
- Nakamura M, Barber AJ, Antonetti DA, LaNoue KF, Robinson KA, Buse MG, et al. Excessive Hexosamines Block the Neuroprotective Effect of Insulin and Induce Apoptosis in Retinal Neurons. *J Biol Chem*. 2001 Nov;276(47):43748–55.
- Rodrigues EB, Urias MG, Penha FM, Badaró E, Novais E, Meirelles R, et al. Diabetes induces changes in neuroretina before retinal vessels: a spectral-domain optical coherence tomography study. *Int J Retina Vitre*. 2015 Dec;1(1):4.
- Atef M, Asma K, Chaker B, Faïda A, Riadh R. Retinal Fiber Layer and Macular Ganglion Cell Layer Thickness in Diabetic Patients. 2019; 10(1):5.
- Pekel E, Tufaner G, Kaya H, Kaşıkçı A, Deda G, Pekel G. Assessment of optic disc and ganglion cell layer in diabetes mellitus type 2. *Medicine (Baltimore)*. 2017 Jul;96(29):e7556.
- Pollreizs A, Desissaire S, Sedova A, Hajdu D, Datlinger F, Schwarzhans F, et al. Early Identification of Retinal Neuropathy in Subclinical Diabetic Eyes by Reduced Birefringence of the Peripapillary Retinal Nerve Fiber Layer. *Investig Ophthalmology Vis Sci*. 2021 Apr 19;62(4):24.
- Reis A, Mateus C, Melo P, Figueira J, Cunha-Vaz J, Castelo-Branco M.

- Neuroretinal Dysfunction With Intact Blood-Retinal Barrier and Absent Vasculopathy in Type 1 Diabetes. *Diabetes*. 2014 Nov;63(11):3926–37.
- Grzybowski A, Brona P, Lim G, Ruamviboonsuk P, Tan GSW, Abramoff M, et al. Artificial intelligence for diabetic retinopathy screening: a review. *Eye*. 2020 Mar 1;34(3):451–60.
  - Tey KY, Teo K, Tan ACS, Devarajan K, Tan B, Tan J, et al. Optical coherence tomography angiography in diabetic retinopathy: a review of current applications. *Eye Vis*. 2019 Dec;6(1):37.